36.61
1.41 (4.01%)
| Penutupan Terdahulu | 35.20 |
| Buka | 35.57 |
| Jumlah Dagangan | 1,016,532 |
| Purata Dagangan (3B) | 1,890,952 |
| Modal Pasaran | 3,225,869,312 |
| Harga / Pendapatan (P/E Ke hadapan) | 28.65 |
| Harga / Jualan (P/S) | 19.13 |
| Harga / Buku (P/B) | 68.60 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 7 May 2026 |
| Margin Operasi (TTM) | -1,135.42% |
| EPS Cair (TTM) | -1.71 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 5.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 297.04% |
| Nisbah Semasa (MRQ) | 2.93 |
| Aliran Tunai Operasi (OCF TTM) | -99.23 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -64.38 M |
| Pulangan Atas Aset (ROA TTM) | -37.66% |
| Pulangan Atas Ekuiti (ROE TTM) | -203.98% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Drug Manufacturers - Specialty & Generic (US) | Bercampur | Menaik |
| Drug Manufacturers - Specialty & Generic (Global) | Bercampur | Menaik | |
| Stok | Liquidia Corporation | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | -5.0 |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 0.5 |
| Purata | -0.20 |
|
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil. |
|
| Sektor | Healthcare |
| Industri | Drug Manufacturers - Specialty & Generic |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 13.64% |
| % Dimiliki oleh Institusi | 65.04% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Caprock Group, Llc | 31 Dec 2025 | 1,783,921 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 55.00 (HC Wainwright & Co., 50.23%) | Beli |
| 55.00 (Jefferies, 50.23%) | Beli | |
| Median | 54.00 (47.50%) | |
| Rendah | 44.00 (Wells Fargo, 20.19%) | Beli |
| Purata | 51.60 (40.95%) | |
| Jumlah | 5 Beli | |
| Harga Purata @ Panggilan | 35.84 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| HC Wainwright & Co. | 06 Mar 2026 | 55.00 (50.23%) | Beli | 36.03 |
| Wells Fargo | 06 Mar 2026 | 44.00 (20.19%) | Beli | 36.03 |
| BTIG | 05 Mar 2026 | 50.00 (36.57%) | Beli | 34.52 |
| 13 Jan 2026 | 49.00 (33.84%) | Beli | 38.09 | |
| Needham | 05 Mar 2026 | 54.00 (47.50%) | Beli | 34.52 |
| 25 Feb 2026 | 52.00 (42.04%) | Beli | 30.00 | |
| Jefferies | 13 Jan 2026 | 55.00 (50.23%) | Beli | 38.09 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| BLOCH STEPHEN M | - | 35.90 | -70,234 | -2,473,667 |
| MOOMAW SCOTT | - | 35.50 | -18,314 | -650,147 |
| Jumlah Keseluruhan Kuantiti Bersih | -88,548 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -3,123,814 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 35.77 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| BLOCH STEPHEN M | Pengarah | 27 Mar 2026 | Jual (-) | 62,550 | 35.03 | 2,191,127 |
| BLOCH STEPHEN M | Pengarah | 26 Mar 2026 | Jual (-) | 7,684 | 36.77 | 282,541 |
| MOOMAW SCOTT | Pegawai | 23 Mar 2026 | Jual automatik (-) | 18,314 | 35.50 | 650,147 |
| MOOMAW SCOTT | Pegawai | 23 Mar 2026 | Pelaksanaan pilihan | 17,000 | - | - |
| Tarikh | Jenis | Butiran |
|---|---|---|
| 27 Jan 2026 | Pengumuman | Liquidia to Present Clinical Data Across Its Portfolio at the Pulmonary Vascular Research Institute 2026 Annual Congress |
| 09 Jan 2026 | Pengumuman | Liquidia Corporation Announces Preliminary Full-Year 2025 YUTREPIA Net Sales and Corporate Update |
| 07 Jan 2026 | Pengumuman | Liquidia Corporation to Present at 44th Annual J.P. Morgan Healthcare Conference |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |